Ex Vivo CD34+ –Selected T Cell–Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response

Highlights • The day 180 incidence of grades II to IV acute graft-versus-host disease and the 3-year incidence of chronic graft-versus-host disease were low after ex vivo CD34+ –selected T cell–depleted allogeneic hematopoietic stem cell transplantation • Acute graft-versus-host disease therapy response was high in the ex vivo CD34+ –selected T cell–depleted allograft recipients • The 1-year and 3-year probabilities of chronic graft-versus-host disease–free/relapse-free survival were high after ex vivo CD34+ –selected T cell–depleted allogeneic hematopoietic stem cell transplantation • Ex vivo CD34+ –selected T cell depletion is a calcineurin inhibitor–free strategy for the prevention of acute and chronic graft-versus-host disease in patients with acute leukemia and myelodysplastic syndrome